An Alderley Park-based biotech organisation is broadening its focus and “building critical mass” as it develops new drugs and a new pipeline of opportunities to fight infectious diseases.<\/p>\n
It has unveiled a new identity with The AMR Centre now to be known as Infex Therapeutics.<\/p>\n
The organisation, which focused on Antimicrobial Resistance (AMR), is taking its proven drug development model and its expertise and putting them to work in the wider infectious disease sector.<\/p>\n
Infex is a UK leader in tackling the health crisis around the dwindling supply of effective antibiotics.<\/p>\n
Executive director Peter Jackson said: \u201cWe are building critical mass as a clinical development organisation and have identified new pipeline of opportunities across the wider infectious disease sector.<\/p>\n
“The launch of Infex Therapeutics gives us a clearer identity and a better reflection of our business model. Our focus is on developing clinical stage drugs to treat infectious diseases.”<\/p>\n
Infex Therapeutics starts out with a portfolio of innovative drugs in development and an exciting pipeline of new opportunities across a range of diseases and pathogens.<\/p>\n
It has more than \u00a310m of partner revenues and non-dilutive grants already contracted over the next three years with more in the pipeline. These projects include a co-development agreement with a US biotech partner on a new gonorrhoea drug.<\/p>\n
The company is portfolio of new drugs includes an anti-virulence program, COT-143, through an agreement with the Japanese pharma company Shionogi. This therapy targets a hard to treat drug-resistant pathogen that features in non-cystic fibrosis bronchiectasis and other lung diseases.<\/p>\n
Jackson added: \u201cOur team has proven capability and expertise in the acquisition and development of a new generation of therapies to meet the rising burden of critical priority infections to address unmet patient needs.<\/p>\n
“We will identify and acquire promising technologies then deliver assets with compelling target product profiles that are attractive to out-license to major pharmaceutical companies.<\/p>\n
\u201cMore importantly, we will be bringing a new portfolio of drugs into clinical trials to treat patients suffering from life-threatening critical-priority infections.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
Organisation widens its infectious diseases fight from North West base<\/p>\n","protected":false},"author":18,"featured_media":2067185,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"coauthors":[81],"class_list":["post-2067182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-featured-story"],"yoast_head":"\n